Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | TA-TMA: an increasingly identified complication post-transplant

Eleni Gavriilaki • 31 Aug 2020
EBMT 2020
Anemias General Antibodies Defibrotide Eculizumab Narsoplimab Ruxolitinib

Eleni Gavriilaki, MD, PhD, George Papanicolaou Hospital, Thessaloniki, Greece, discusses thrombotic microangiopathy (TMA), specifically highlighting transplant-associated TMA (TA-TMA). TA-TMA is an endothelial damage syndrome that’s increasingly found as a complication of autologous and allogeneic hematopoietic cell transplantation. Dr Gavriilaki goes on to discuss the therapeutic options for this complication such as the monoclonal antibody narsoplimab, which targets MASP-2. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Eleni Gavriilaki

The current approach to response assessment in TA-TMA
1:36
The current approach to response assessment in TA-TMA
Eleni Gavriilaki • 25 Mar 2026
The current approach to severity scoring in TA-TMA
1:21
The current approach to severity scoring in TA-TMA
Eleni Gavriilaki • 25 Mar 2026
Moving the field forward in TA-TMA: insights from an educational session
2:26
Moving the field forward in TA-TMA: insights from an educational session
Eleni Gavriilaki • 25 Mar 2026
Endothelial injury syndromes in hematology: unifying the terminology
1:44
Endothelial injury syndromes in hematology: unifying the terminology
Eleni Gavriilaki • 13 Jun 2025

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals